HISAMITSU PHARMACEUTICAL CO.,INC. Logo

HISAMITSU PHARMACEUTICAL CO.,INC.

A global leader in transdermal drug delivery systems for OTC and prescription pain relief.

4530 | T

Overview

Corporate Details

ISIN(s):
JP3784600003
LEI:
Country:
Japan
Address:
鳥栖市田代大官町408番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hisamitsu Pharmaceutical Co., Inc. is a multinational pharmaceutical corporation engaged in the research, development, manufacture, and sale of prescription and over-the-counter (OTC) products. The company is a global leader in pain relief solutions, specializing in transdermal drug delivery systems. Its core portfolio features external analgesic and anti-inflammatory preparations, including well-known patches, plasters, and poultices. Hisamitsu actively pursues innovation in its field, with ongoing clinical research into next-generation technologies like microneedle drug delivery systems. Established in 1834, the company leverages its long history and expertise to market its therapeutic products worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:40
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 29.4 KB
2025-10-10 08:28
Registration Form
確認書
Japanese 9.2 KB
2025-10-10 08:25
Interim Report
半期報告書-第124期(2025/03/01-2026/02/28)
Japanese 240.4 KB
2025-10-03 08:43
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.7 KB
2025-09-03 08:36
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-08-05 08:45
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2025-05-23 08:00
Registration Form
確認書
Japanese 9.5 KB
2025-05-23 07:58
Governance Information
内部統制報告書-第123期(2024/03/01-2025/02/28)
Japanese 24.0 KB
2025-05-23 07:55
Registration Form
有価証券報告書-第123期(2024/03/01-2025/02/28)
Japanese 1.7 MB
2025-05-23 07:44
Post-Annual General Meeting Information
臨時報告書
Japanese 28.3 KB
2024-10-11 08:12
Registration Form
確認書
Japanese 9.2 KB
2024-10-11 08:08
Interim Report
半期報告書-第123期(2024/03/01-2025/02/28)
Japanese 244.4 KB
2024-07-12 08:12
Quarterly Report
確認書
Japanese 9.2 KB
2024-07-12 08:09
Quarterly Report
四半期報告書-第123期第1四半期(2024/03/01-2024/05/31)
Japanese 179.7 KB
2024-05-24 08:14
Registration Form
確認書
Japanese 9.5 KB

Automate Your Workflow. Get a real-time feed of all HISAMITSU PHARMACEUTICAL CO.,INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HISAMITSU PHARMACEUTICAL CO.,INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HISAMITSU PHARMACEUTICAL CO.,INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany
BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia
BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland
BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom
BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland
BIOV
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden
BIOVIC
BIOVIE INC. Logo
Develops drug therapies for Alzheimer's, Parkinson's, and advanced liver diseases by targeting inflammation.
United States of America
BIVI
BioXcel Therapeutics, Inc. Logo
AI-driven biopharma developing treatments for neuroscience and immuno-oncology.
United States of America
BTAI
Black Diamond Therapeutics, Inc. Logo
Develops precision oncology drugs targeting mutation families in lung and brain cancers.
United States of America
BDTX
BL Pharmtech Corp. Logo
Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.
South Korea
065170

Talk to a Data Expert

Have a question? We'll get back to you promptly.